Suchergebnisse - "Miossec, P"

PubPharm (305)

1

Proinflammatory cytokines and cardio-vascular risk : From myocardial infarction tocytokine storm of COVID-19

enthalten in: Bulletin de l'Academie nationale de medecine | 2021

von Miossec, P.

2

Interleukin-17 and lupus : enough to be a target? For which patients?

enthalten in: Lupus | 2020

von Robert, M. | Miossec, P.

3

IL-17 and TNF-α co-operation contributes to the proinflammatory response of hepatic stellate cells

enthalten in: Clinical and experimental immunology | 2019

von Beringer, A. | Miossec, P.

4

IL‐17 and TNF‐α co‐operation contributes to the proinflammatory response of hepatic stellate cells

enthalten in: Clinical & Experimental Immunology | 2019

von Beringer, A. | Miossec, P.

5

Synergistic effect of interleukin-17 and tumour necrosis factor-α on inflammatory response in hepatocytes through interleukin-6-dependent and independent pathways

enthalten in: Clinical and experimental immunology | 2018

von Beringer, A. | Thiam, N. | Molle, J. | +2

6

Role of podoplanin in the high interleukin-17A secretion resulting from interactions between activated lymphocytes and psoriatic skin-derived mesenchymal cells

enthalten in: Clinical and experimental immunology | 2016

von Noack, M. | Ndongo-Thiam, N. | Miossec, P.

7

Role of podoplanin in the high interleukin‐17A secretion resulting from interactions between activated lymphocytes and psoriatic skin‐derived mesenchymal cells

enthalten in: Clinical and experimental immunology | 2016

von Noack, M. | Ndongo‐Thiam, N. | Miossec, P.

8

Une cohorte prospective sur la morbi/mortalité cardiovasculaire chez des patients atteints de sclérodermie systémique

enthalten in: Revue de médecine interne | 2016

von Dhelft, F. | Laville, M. | Ninet, J. | +3

9

P331 Le lixisénatide, en addition à une insuline basale, est plus efficace lorsque la glycémie à jeun est bien contrôlée

enthalten in: Diabetes & metabolism | 2014

von Raccah, D. | Vidal, J. | Aronson, R. | +6

10

P1130 Efficacité et tolérance du lixisénatide chez le sujet diabétique de type 2 âgé (≥ 65 ans) et très âgé (≥ 75 ans) : analyse des essais de phase III GetGoal

enthalten in: Diabetes & metabolism | 2013

von Raccah, D. | Miossec, P. | Esposito, V. | +4

1
2
3
4
5
6
7
8
9
10
11
Nächster »
[31]